Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Barrios

Showing results (141-150 of 183) with videos related to

Pageof 19
Sort By:
Clinical Lung Cancer|April 15, 2018
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Frontiers in Oncology|April 21, 2020
<i>ESR1</i> Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor TherapyTomás Reinert, Susana Ramalho, Vivian Castro Antunes de Vasconcelos, et al.
Ecancermedicalscience|May 22, 2024
Improving access to cancer clinical research in Brazil: recent advances and new opportunities. Expert opinions from the 4th CURA meeting, São Paulo, 2023Heloisa Resende, Roberto J Arai, Carlos H Barrios, et al.
Immunity|September 17, 2017
SIDT2 Transports Extracellular dsRNA into the Cytoplasm for Innate Immune RecognitionTan A Nguyen, Blake R C Smith, Michelle D Tate, et al.
Gynecologic Oncology|June 1, 2015
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinomaOren Smaletz, Maria D P E Diz, Claudio C do Carmo, et al.
JCO Global Oncology|May 6, 2021
Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)Aline B Lara Gongora, Gustavo Werutsky, Denis L Jardim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancerSuresh S Ramalingam, Mikhail Shtivelband, Ross A Soo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinomaRobert J Motzer, Carlos H Barrios, Tae Min Kim, et al.
Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.
Pageof 19

Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
Clinical Lung Cancer|April 15, 2018
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Frontiers in Oncology|April 21, 2020
<i>ESR1</i> Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor TherapyTomás Reinert, Susana Ramalho, Vivian Castro Antunes de Vasconcelos, et al.
Ecancermedicalscience|May 22, 2024
Improving access to cancer clinical research in Brazil: recent advances and new opportunities. Expert opinions from the 4th CURA meeting, São Paulo, 2023Heloisa Resende, Roberto J Arai, Carlos H Barrios, et al.
Immunity|September 17, 2017
SIDT2 Transports Extracellular dsRNA into the Cytoplasm for Innate Immune RecognitionTan A Nguyen, Blake R C Smith, Michelle D Tate, et al.
Gynecologic Oncology|June 1, 2015
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinomaOren Smaletz, Maria D P E Diz, Claudio C do Carmo, et al.
JCO Global Oncology|May 6, 2021
Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)Aline B Lara Gongora, Gustavo Werutsky, Denis L Jardim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancerSuresh S Ramalingam, Mikhail Shtivelband, Ross A Soo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinomaRobert J Motzer, Carlos H Barrios, Tae Min Kim, et al.
Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.
Pageof 19